Huang Xiao-Min, Li Xia, Deng Jie, Chen Jiong, Qian Liang
Department of Anesthesiology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Centre for Respiratory and Critical Care Medicine, The University of Hong Kong-Shen Zhen Hospital, Shenzhen, China.
Front Oncol. 2025 Jan 16;14:1519728. doi: 10.3389/fonc.2024.1519728. eCollection 2024.
Totally implantable venous access port (TIVAP), a novel intravenous infusion system that is used for long-term intravenous treatment, has become increasingly popular among cancer patients undergoing chemotherapy and other patients requiring long-term intravenous infusions. This technology has been introduced into clinical practice in China, with successful results. Nevertheless, there are still certain problems; for instance, China has not set up a specialized regulatory agency to oversee research and set guidelines for the comprehensive life-cycle management of TIVAP. Additionally, there exists a disparity in standardized operations and complication management related to TIVAP, which has resulted in variable outcomes, complications, and patient satisfaction with TIVAP implantation across different medical units in China. Therefore, this article aims to provide a systematic overview of the clinical applications and maintenance of TIVAP, both domestically and internationally. Furthermore, this review investigated the latest strategies and associated research on TIVAP implantation and complication management, aiming to provide a basis for standardized surgical and maintenance procedures, protocols to minimize complications, and approaches for enhancing the overall quality of life for patients.
完全植入式静脉输液港(TIVAP)是一种用于长期静脉治疗的新型静脉输液系统,在接受化疗的癌症患者和其他需要长期静脉输液的患者中越来越受欢迎。这项技术已在中国引入临床实践,并取得了成功。然而,仍然存在一些问题;例如,中国尚未设立专门的监管机构来监督研究并为TIVAP的全生命周期管理制定指南。此外,TIVAP相关的标准化操作和并发症管理存在差异,这导致中国不同医疗单位在TIVAP植入的结果、并发症和患者满意度方面存在差异。因此,本文旨在对国内外TIVAP的临床应用和维护进行系统概述。此外,本综述调查了TIVAP植入和并发症管理的最新策略及相关研究,旨在为标准化手术和维护程序、最小化并发症的方案以及提高患者整体生活质量的方法提供依据。